GlassScriptPhysician profile
David S Kamrava
NPI 1285800359
$5,742.61
in general payments reported to CMS, 2019-2025
25 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,384 · 2020: $475 · 2021: $413 · 2022: $835 · 2023: $738 · 2024: $723 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,618 · Education: $18.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,617.73 |
| Education | $18.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,283.31 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $883.24 | 2019-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $696.96 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Mylan Specialty L.P. | $499.53 | 2022-2024 | Yupelri |
| Grifols USA, LLC | $423.49 | 2019-2024 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $286.10 | 2019-2025 | Dupixent |
| Insmed, INC. | $245.91 | 2023-2025 | Arikayce, Brinsupri |
| Viatris Specialty LLC | $236.20 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $231.55 | 2019-2023 | Uptravi |
| Amgen INC. | $140.33 | 2021-2025 | Tezspire |
| Advanced Respiratory, INC | $135.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $122.00 | 2019 | |
| Abiomed | $93.37 | 2024-2025 | Impella |
| Sunovion Pharmaceuticals INC. | $90.15 | 2019 | |
| Verona Pharma, INC. | $84.40 | 2025 | Ohtuvayre |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $48.93 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $47.76 | 2021-2025 | Zerbaxa |
| Inspire Medical Systems, INC. | $36.32 | 2025 | Inspire |
| Vifor Pharma, INC. | $35.00 | 2024 | Zemaira |
| Allergan, INC. | $29.20 | 2019 | |
| Baxter Healthcare | $27.25 | 2023 | Hillrom - Volara System |
| Mayne Pharma Commercial LLC | $22.76 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.28 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $13.91 | 2021 | |
| Ceribell, INC. | $10.99 | 2023 | Ceribell Rapid Response Eeg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kamrava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.